Incyte Corporation reported positive topline results from the Phase III inMIND clinical trial of its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in relapsed or refractory follicular lymphoma (FL) on 16 August and said it will file a supplemental biologics license application (sBLA) with the US Food and Drug Administration for the indication by the end of this year. FL is one of two indications the company is targeting for near- to mid-term growth in an increasingly crowded drug class.
Key Takeaways
-
Incyte plans to seek US FDA approval for Monjuvi in relapsed or refractory follicular lymphoma (FL) by the end of 2024 based on positive topline results from the inMIND study.
In February, Wilmington, DE-based Incyte agreed to pay $25m to obtain exclusive global rights to Monjuvi from its partner
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
